🐻 DHR $4.6M Put Bet - Smart Money Hedging Before $10B Masimo Deal Closes!

📅 February 17, 2026 | 🔥 Unusual Activity Detected

---

🎯 The Quick Take

Someone just dropped $4.6 MILLION on DHR puts this morning at 10:02:46! This massive bearish bet bought 6,356 contracts of $210 strike puts expiring in just 3 days - with DHR trading at $204.59 after announcing a controversial $9.9 billion Masimo acquisition earlier today. With the stock already down 3.4% on the news and the put strike sitting in-the-money, this looks like aggressive institutional positioning for more downside. Translation: Big money expects DHR to keep falling through Friday's expiration!

---

📊 Company Overview

Danaher Corporation (DHR) is a global life sciences and diagnostics powerhouse that evolved from a real estate firm into one of the most respected acquirers in healthcare:

• Market Cap: $150.3 Billion
• Industry: Industrial Instruments for Measurement, Display, and Control
• Current Price: $204.59 (down 3.4% today)
• 52-Week Range: $171.00 - $242.80
• Employees: 63,000 worldwide
• Primary Business: Scientific instruments and consumables for life sciences, diagnostics (Cepheid, Beckman Coulter, Cytiva)

---

💰 The Option Flow Breakdown

The Tape (February 17, 2026 @ 10:02:46):

🤓 What This Actually Means

This is an aggressive bearish bet on continued downside! Here's what went down:

• 💸 Huge premium paid: $4.6M ($7.21 per contract x 6,356 contracts)
• 🎯 In-the-money strike: $210 puts already ITM with stock at $204.59 - $5.41 of intrinsic value
• ⏰ Ultra-short duration: Only 3 days to expiration (Friday February 20)
• 📊 Size matters: 6,356 contracts represents 635,600 shares worth ~$130M notional exposure
• 🔥 Volume vs OI: 6,400 volume against 9,400 open interest = significant NEW positioning

What's really happening here: This trader bought in-the-money puts on the SAME DAY DHR announced its $9.9 billion Masimo acquisition. The stock is already down 3.4% on the news, and they're betting it falls further before Friday. With the put strike at $210 and stock at $204.59, they're already sitting on $5.41/share of intrinsic value. They paid $7.21 total, meaning they only need the stock to stay below $202.79 to profit. This is conviction that the Masimo deal selloff has more room to run.

Unusual Score: 🔥 EXTREMELY UNUSUAL (Z-Score: 9.14) - This is roughly 9 standard deviations above normal activity! For context, anything above 3 is considered statistically significant. We're talking about activity that might occur a few times per year at most.

---

📈 Technical Setup / Chart Check-Up

YTD Performance Chart

DHR has had a rough start to 2026 - down 11% YTD from around $230 to today's $204.59. The stock started the year optimistically after Q4 2025 earnings beat expectations, but today's Masimo acquisition announcement triggered a sharp selloff.

Key observations:

• 📉 Sharp breakdown: Stock dropped from $212 to $204 on Masimo news - breaking key support
• 🎢 52-week context: Trading near the lower end of its $171-$243 range
• 💔 Multiple support breaks: Violated $216 and now testing $205 area
• ⚠️ Momentum shift: Moving averages issuing sell signals according to StockInvest technical analysis
• 📊 Volume spike: Elevated trading volume on the acquisition news

Gamma-Based Support & Resistance Analysis

Current Price: $204.59

The gamma exposure map reveals critical price levels where market makers have concentrated positioning:

🔵 Support Levels (Put Gamma Below Price):

• $205 - MAJOR support with 2.78B total gamma (STRONGEST FLOOR - we're right here!)
• $202.50 - Secondary support at 0.44B gamma (1.3% below current)
• $200 - Round number psychological support with 0.87B gamma (2.5% below)
• $195 - Deep support at 1.29B gamma (nearly 5% below - bearish target)

🟠 Resistance Levels (Call Gamma Above Price):

• $207.50 - Immediate ceiling with 0.60B gamma (1.4% overhead)
• $210 - HEAVY resistance at 9.90B gamma (THIS IS THE PUT STRIKE! 2.6% above)
• $215 - Secondary resistance at 3.16B gamma (5% above)
• $220 - Major ceiling at 1.61B gamma (7.5% above)
• $230 - Extended resistance at 0.71B gamma (12% above)

What this means for traders: The $210 strike is NOT a coincidence! The put buyer chose EXACTLY the level with maximum gamma concentration (9.90B - by far the largest). This means market makers have massive hedging obligations at $210. When price approached $210 and failed, dealers had to sell to hedge, accelerating the decline. Now with price at $204.59 and the $210 resistance confirmed, the path of least resistance is DOWN toward $200-$195 support.

Notice the setup: Stock is sitting RIGHT at $205 major support with massive put gamma above at $210. Either $205 holds and we bounce, or it breaks and momentum accelerates toward $195-$200. The put buyer is betting on the BREAK.

Net GEX Bias: Bearish (3.5B call gamma vs 20.7B put gamma) - Heavy put gamma dominance suggests dealers will amplify downside moves.

Implied Move Analysis

Options market pricing for upcoming expirations:

• 📅 Weekly (Feb 20 - 3 days - THIS TRADE!): ±$4.55 (±2.21%) → Range: $200.76 - $209.85
• 📅 Monthly OPEX (Feb 20 - same as weekly): ±$4.55 (±2.21%) → Range: $200.76 - $209.85
• 📅 Quarterly Triple Witch (Mar 20 - 31 days): ±$12.58 (±6.13%) → Range: $192.73 - $217.88

Translation for regular folks: The options market expects DHR to trade in a $200.76 to $209.85 range by Friday's expiration. The put buyer paid $7.21 for puts struck at $210 - meaning they NEED the stock below $202.79 to profit. That's just barely below the implied range floor of $200.76. They're betting the selloff pushes through the expected range!

The March quarterly expiration shows a much wider expected range ($192.73 - $217.88), suggesting traders expect elevated volatility around Q1 earnings and Masimo deal developments.

Key insight: The $200.76 implied move lower bound is dangerously close to the major $200 gamma support level. A break below $200 could trigger accelerated selling toward the $195 support zone.

---

🎪 Catalysts

🔥 Today's Catalyst - Masimo Acquisition Announcement (February 17, 2026)

The MAJOR catalyst driving this put activity - Danaher announced this morning a definitive agreement to acquire Masimo Corporation:

• 💰 Deal Value: $9.9 billion ($180 per share in cash, 38.3% premium for Masimo)
• ⏰ Expected Close: H2 2026, pending regulatory approvals
• 🏢 Strategic Fit: Masimo will operate standalone within Danaher's Diagnostics segment
• 📊 Expected Synergies: $125M+ annual cost synergies; $50M+ revenue synergies by year 5

Why the market is selling: According to Tokenist's analysis, investors are concerned about:

• 🤔 "Diworsification" worries: Masimo's hospital monitoring is lower-growth than core genomics/bioprocessing
• ⚠️ Integration risk: $9.9B deal coinciding with CFO transition creates execution headwinds
• 💸 Premium paid: 38.3% premium seems rich for a slower-growth asset
• 📉 Timing questions: Why deploy capital now vs. waiting for bioprocessing recovery?

📅 Recent Catalysts (Already Happened)

Q4 2025 Earnings Beat (January 28, 2026)

DHR actually beat expectations on both revenue and earnings:

• ✅ Revenue: $6.84B (+4.5% YoY) - Beat
• ✅ Non-GAAP EPS: $2.23 (+4.0% YoY) vs $2.18 estimate - Beat
• ✅ Free Cash Flow: $1.8B - Strong
• 📈 Bioprocessing consumables returned to high-single-digit growth

Cepheid GI Panel FDA Clearance (January 20, 2026)

Cepheid received FDA clearance for its Xpert GI Panel - first highly multiplexed test for Cepheid, strengthening diagnostics competitive position.

CFO Transition (Effective February 28, 2026)

Matthew McGrew transitioning to EVP as Matthew Gugino becomes CFO. Leadership change during major acquisition creates uncertainty.

🔮 Upcoming Catalysts

Q1 2026 Earnings (Expected Late April 2026)

Based on MarketBeat's earnings calendar, Q1 2026 earnings expected around April 21-28. Management guidance from Stock Titan:

• FY 2026 Core Revenue Growth: 3-6%
• FY 2026 Adjusted EPS: $8.35 - $8.50
• Expected Margin Expansion: 100+ bps

Masimo Deal Regulatory Review (H2 2026)

Per InsideArbitrage, key milestones include FTC/DOJ antitrust review and Masimo shareholder vote. Any regulatory concerns could further pressure DHR.

Bioprocessing Equipment Recovery (H2 2026)

According to Investing.com analysis, management expects equipment sales to recover from flat to low-single-digit growth in H2 2026. Order book "fully supports high-single-digit growth" for the year.

---

🎲 Price Targets & Probabilities

Using gamma levels, implied move data, and the Masimo catalyst, here are the scenarios through Friday's expiration:

📈 Bull Case (20% probability)

Target: $210-$215

How we get there:

• 📈 Market digests Masimo deal positively after initial shock
• 💪 Analysts come out defending strategic rationale
• 🎯 Stock reclaims $207.50 resistance and squeezes toward $210 gamma wall
• 📊 Short-term oversold bounce from $205 support level
• ⏰ Only 3 days - would need rapid sentiment shift

Why it's unlikely:

• Heavy $210 gamma resistance (9.90B) creates natural ceiling
• Deal announced SAME DAY as put trade - negative sentiment fresh
• CFO transition adds execution uncertainty
• Implied move ceiling at $209.85 aligns with resistance

Probability assessment: Only 20% because it requires complete reversal of today's negative reaction with only 3 trading days remaining.

🎯 Base Case (50% probability)

Target: $200-$207 range (CHOPPY)

Most likely scenario:

• ⚖️ Stock stabilizes around $203-$206 as market processes deal
• 📊 Trading within gamma support ($205) and resistance ($207.50) bands
• 💤 Low conviction either direction as investors wait for more details
• 🔄 Put buyer's position oscillates around breakeven
• 📉 Closes Friday somewhere in $200-$207 range

What this means for the put trade: At $203-$206 range, the $210 puts would be worth $4-$7 intrinsic value. The trader paid $7.21, so anything above $202.79 is a loss. Base case suggests modest loss to small gain.

Why 50% probability: Initial selloff may be overdone, but resistance at $210 caps any rally. Stock likely consolidates as market awaits Q1 earnings and deal progress updates.

📉 Bear Case (30% probability)

Target: $195-$200 (BREAKDOWN!)

What could drive this:

• 😰 Analyst downgrades citing Masimo deal concerns
• 📉 Break below $205 gamma support triggers cascade selling
• 🎯 Momentum traders pile on after support break
• 🇨🇳 China headwind concerns resurface (10-12% revenue exposure per TIKR analysis)
• 💸 Broader market weakness amplifies selling
• 🔨 Stock tests $200 psychological level, then $195 gamma support

Critical levels to watch:

• 🛡️ $205: Current major support - MUST HOLD or selling accelerates
• 🛡️ $200: Psychological round number and gamma support
• 🛡️ $195: Deep support level with 1.29B gamma

Put P&L in Bear Case:

• Stock at $200: Puts worth $10.00, profit = $2.79/share x 6,356 = $1.77M gain
• Stock at $195: Puts worth $15.00, profit = $7.79/share x 6,356 = $4.95M gain (107% ROI!)
• Stock at $202.79: Puts worth $7.21 = BREAKEVEN

Probability assessment: 30% because Masimo deal concerns are legitimate, CFO transition adds risk, and technical setup shows bearish momentum. If $205 breaks, path to $195-$200 is open.

---

💡 Trading Ideas

🛡️ Conservative: Wait for Dust to Settle

Play: Stay on sidelines until post-expiration volatility clears

Why this works:

• ⏰ Only 3 trading days until this put expires - too short for new entries
• 💸 Options expensive with elevated IV on acquisition news
• 📊 Stock at technical inflection point - $205 support either holds or breaks
• 🎯 Better entry likely next week after Friday OPEX clears dealer gamma
• 🤔 The $4.6M institutional put buy signals sophisticated players see more risk - why fight it?

Action plan:

• 👀 Monitor $205 support level - break below signals bearish momentum
• 🎯 Look for entry on pullback to $195-$200 range for long-term value position
• ✅ Wait for analyst commentary on Masimo deal (expect reports by Wednesday)
• ⏰ Revisit after February 20 OPEX clears

Risk level: Minimal (cash position) | Skill level: Beginner-friendly

⚖️ Balanced: Put Spread if $205 Breaks

Play: Enter bearish put spread ONLY if $205 support breaks

Structure: Buy $205 puts / Sell $195 puts (March 20 expiration)

Why this works:

• 🎢 Defined risk spread ($10 wide = $1,000 max risk per spread)
• 📊 Targets gamma support zone at $195-$200
• ⏰ March expiration gives 31 days - captures Q1 earnings positioning
• 🎯 Breakeven around $200-$201 aligns with bear case target

Entry criteria:

• ❌ ONLY enter if DHR closes below $205 (support break confirmation)
• 🎯 Target entry: DHR at $202-$204 with confirmed breakdown
• ⏰ Enter within 1-2 days (before too much premium decay)

Estimated P&L:

• 💰 Pay ~$3-4 net debit per spread
• 📈 Max profit: $600-700 if DHR below $195 at March expiration
• 📉 Max loss: $300-400 if DHR above $205

Risk level: Moderate (defined risk, bearish directional) | Skill level: Intermediate

🚀 Aggressive: Follow the Whale - Near-Term Puts

Play: Mirror the institutional put positioning with smaller size

Structure: Buy $207.50 puts (February 20 expiration) - slightly OTM for cheaper entry

Why this could work:

• 🐋 $4.6M whale just bet on this exact thesis - follow smart money
• 📉 Stock already in downtrend, breaking support levels
• ⏰ Masimo deal concerns likely persist through week
• 🎯 If $205 breaks, quick move to $200 provides 3-4x return potential
• 📊 High gamma at $210 means dealers amplify downside moves

Why this could blow up (SERIOUS RISKS):

• 💸 3-DAY EXPIRATION: Extreme theta decay - could lose 100%
• ⏰ Binary outcome: Either it works fast or you lose everything
• 📉 Already down 3.4%: Easy bounce could wipe out position
• ⚠️ Short-term noise: Headlines could swing price either direction

Estimated P&L:

• 💰 Cost: ~$3-4 per contract for $207.50 puts
• 📈 Profit scenario: Stock drops to $200 = puts worth ~$7.50 (100%+ gain)
• 📉 Loss scenario: Stock bounces to $207+ = lose 50-100% of premium

CRITICAL WARNING: Only for traders who understand expiration week gamma risk and can afford to lose entire position.

Risk level: HIGH | Skill level: Advanced only

---

⚠️ Risk Factors

Don't get caught by these potential landmines:

• 💸 $9.9B Masimo deal execution risk: Per Financial Content analysis, the acquisition occurring simultaneously with CFO transition creates elevated integration risk. DHR is paying a 38.3% premium for a business some view as lower-growth than core operations.

• 🇨🇳 China headwinds: According to TIKR analysis, DHR has 10-12% revenue exposure to China. Volume-Based Procurement creating $75-100M annual headwind in Diagnostics. Preference for domestic suppliers pressuring market share.

• 📊 Conservative 2026 guidance: Management guiding only 3-6% core revenue growth per Stock Titan. At 27x forward P/E, limited upside unless execution surprises to upside.

• ⚖️ Bioprocessing recovery uncertainty: Equipment sales still flat according to Investing.com. Recovery thesis depends on customer destocking ending - timing uncertain.

• 🔄 CFO transition at critical moment: Matthew McGrew departing after 20+ years during largest acquisition since Cytiva creates leadership uncertainty.

• 📉 Technical breakdown: Stock broke multiple support levels today. StockInvest technical analysis shows moving averages issuing sell signals. Below $205 could test $175 historical support.

• 🐋 Smart money positioning bearish: The $4.6M institutional put buy with Z-score of 9.14 signals sophisticated players expect further downside. When institutions pay $4.6M for 3-day protection, they see real risk.

---

🎯 The Bottom Line

Real talk: Someone just spent $4.6 MILLION betting DHR keeps falling through Friday after today's Masimo acquisition announcement. This isn't blind speculation - the trade was executed HOURS after the $9.9B deal was announced, with the stock already down 3.4%. They chose the $210 strike because that's where MAXIMUM gamma resistance sits - a level the stock is very unlikely to reclaim this week.

What this trade tells us:

• 🎯 Sophisticated player expects continued selloff through Friday expiration
• 💰 They're betting $4.6M that $205 support breaks and we see $200 or lower
• ⏰ The 3-day duration shows HIGH conviction - they don't need much time
• 📊 Z-score of 9.14 means this is statistically EXTREMELY rare activity
• 🐋 When institutions deploy this much capital on short-dated puts, PAY ATTENTION

This IS a bearish signal - but be careful chasing it with only 3 days left.

If you own DHR:

• ✅ Consider trimming 20-30% here if concerned about deal integration risk
• 📊 Set MENTAL STOP at $200 - break below signals more downside
• 🎯 Long-term thesis (bioprocessing recovery, diagnostics strength) still intact
• 🛡️ Don't panic sell on one day's action - but don't ignore the signal either

If you're watching from sidelines:

• ⏰ Don't chase puts with 3 days left - theta decay is brutal
• 🎯 Wait for $195-$200 range for better long entry if you like DHR fundamentals
• 📈 Analyst consensus remains Strong Buy with $267 average target - 30%+ upside if deal concerns fade
• 🔄 Better risk/reward after OPEX clears and dust settles

If you're bearish:

• 🎯 This week is probably too late for new put entries - premium expensive
• 📊 March put spreads offer better risk/reward if you expect continued weakness
• ⚠️ Watch $205 level closely - break below confirms bearish thesis
• 📉 First target $200, then $195 if momentum persists

Mark your calendar - Key dates:

• 📅 February 20 (Friday) - Weekly/Monthly OPEX - this put trade expires
• 📅 February 28 - New CFO Matthew Gugino takes over
• 📅 Late April 2026 - Q1 2026 earnings expected
• 📅 H2 2026 - Masimo deal expected to close

Final verdict: The $4.6M put buy is a clear signal that institutional money expects DHR to remain under pressure near-term as the market digests the Masimo acquisition. The deal raises legitimate concerns about capital allocation and integration risk during a CFO transition. However, DHR's long-term fundamentals remain solid - bioprocessing recovery on track, Cepheid launching new products, and analyst price targets average $267 (30%+ above current).

Short-term pain, long-term opportunity. If you're a patient investor, the selloff may create a compelling entry point in the $195-$200 range. If you're a trader, respect the institutional put flow and don't fight the tape this week.

When $4.6M bets against a stock on acquisition day, the smart play is to wait for clarity before deploying capital. 💪

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. This analysis is for educational purposes only and not financial advice. Past performance doesn't guarantee future results. The Z-score of 9.14 indicates this trade's unusual size relative to recent DHR history - it does not imply the trade will be profitable or that you should follow it. Always do your own research and consider consulting a licensed financial advisor before trading. Short-dated options (3 days to expiration) carry extreme theta decay risk and can lose 100% of value rapidly.

---

About Danaher Corporation: Danaher Corporation designs and manufactures scientific instruments and consumables for life sciences and diagnostic industries, operating premier brands including Cepheid, Beckman Coulter, Cytiva, Radiometer, and Leica Biosystems, with a market cap of $150.3 billion.